A routine software update from a vendor can silently activate AI-driven decision-making, bypassing traditional due‑diligence controls such as purchase orders, contracts, or formal risk reviews. Because the change is delivered through a release note rather than a new product acquisition, it often escapes the scrutiny of legal, procurement, and risk teams, leaving organizations vulnerable to automated actions that could halt shipments or alter quality‑control processes without oversight.
The article illustrates this risk with a hypothetical wellness‑supplement plant where a vendor’s update adds “AI‑assisted deviation triage” by default. Existing risk assessments remain tied to the previous software version, and no stakeholder recognizes the new capability. The author urges companies to treat release notes themselves as third‑party risk events, demanding explicit review and approval before enabling such functionality.
Source: Corporate Compliance Insights